Clinical heart transplantation, pioneered by Shumway and his colleagues at StanfordUniversity in the 1960s (1), has emerged as al eading therapy for end stage heart disease. Since its inception, over 73,000 heart transplants have been performed worldwide (2). The most recent data from the InternationalSociety for Heart and Lung Transplantation (ISHLT) estimates that annually greater than 4,000 heart transplants arep erformed worldwide. The number of donor organs currently limits the availability of this therapy,and in the United States alone, mortality on the heart transplant waiting list is over 15%. Longterm outcomes for heart transplant recipientsfar surpasses medicalt herapy,w ith survival estimates of 81% at 1y ear,6 8% at 5y ears, and 50% at 10 years post-transplantation.I nr ecent years, progress has been madei nas everal areas of clinical heart transplantation. Both donor and recipient selectioncriteria have been liberalized, allowing this therapy to reach awider range of patients. Moreover,optimization of donor management has led to as ignificant increase in donor organ retrieval.S urgical technique has shifteda way from the original biatrial implantation technique described by Shumway and Lower and towardt he morep hysiologic bicaval implantation technique. Finally, improvements in immunosuppression have led to better protection against both acute and chronic forms of rejection.
RECIPIENT SELECTION AND MANAGEMENT
Candidates for heart transplantation should be on maximal medical therapy,which typically consistsof the highest toleratedd ose of an ACE inhibitor (or angiotensin II receptor blockerf or those with ACE function have undergone multi-organ transplantation (heart/kidney or heart/liver respectively). Sixty percent of patients with left ventricular assist devices (LVA D) have evidence of infection, and in this unusual group, the presence of infection does not preclude transplantation.
Relative contraindications to transplantation include ageover 65, myocardial infiltrative disease(e.g. amyloidosis or sarcoidosis), obesity,osteoporosis, active peptic ulcer disease, hepatitis Band Cinfection, psychiatric disorders, substance abuse, and history of medical noncompliance. Several groups have reported experience in transplanting patients over 65, and UCLA introduced the concept of an "alternate list" that matcheso lder patients to organs that areu nacceptable by standardc riteria (5). These include organs from donorso lder than 55 years, organs from donors with positive hepatitis Bo rCs erologies, organs from donorsw ith high inotrope requirements, or organs with coronary artery disease, left ventricular hypertrophy,orleft ventricular dysfunction. Survival in this cohort was 70% one year after transplantation.
DONOR SELECTION AND MANAGEMENT
Defined strategies for management of the organ donor have led to increased rates of organ retrieval. Brain death results in cardiac dysfunction through several mechanisms. With brainstemh erniation, a sudden rise in serum catecholamines ("sympathetic storm") can result in coronary vasoconstriction,subendocardial ischemia, and focal myocardial necrosis. This is followed by ap hase of severeh ypotension (spinals hock) due to decreased sympathetic output and profound endocrine and metabolic abnormalities. During this period,i notropes and vasopressors may be needed to maintain organ perfusion (6). The Papworth group found that aggressive donor management resulted in a3 0% increase in donor organ retrieval (7, 8). They routinely used apulmonary artery (PA) catheter as ahemodynamic guide, and supplemented the donor with ahormone cocktail of vasopressin, T3, insulin, and cortisol. An algorithmfor donor management was issued by leaders in the field following amultidisciplinary meeting in Crystal City, Virginia in 2001 (9). Overall goals for donor management include achieving euvolemia, optimizing cardiac output,a chieving normal acid-base status, and correcting hormonal abnormalities. The goal CVP is 6-10 mm Hg and the goal MAP is ≥60mmHg. Inotropes and vasopressors should be kept at am inimum (for example, the goal for dopamine or dobutamine is <10mcg/kg/min). An initial echocardiogram should be obtained to assess LV function. If the ejection fraction(EF) is greater than or equal to 45%, the organ should be recovered for transplantation. If the EF <45%, aP Ac atheter should be placed to guide hemodynamic management and hormonal therapy should be instituted.Afollow-up echocardiogram should be obtained, and if the EF ≥45%, these resuscitatedhearts can be recovered for transplantation.
Typical characteristics of the heart donor include age <55, absence of chest trauma or cardiac disease (LVd ysfunction, coronary artery disease, valvular disease, or conductiona bnormalities), and negative serologiesf or HIV,h epatitis B, and hepatitis C( see Table 2 ). Diagnostic studies should include an ECG, echocardiogram, and when indicated by age or risk factors, left heart catheterization. Screening left heart catheterization should be obtained for male donors older than 45 and female donors older than 50. The donor must meet hemodynamic criteria, including MAP >60mmHg, on minimal inotropic support.
The donor pool has been broadenedwith the inclusion of extended donor organs, which in some cases can be appropriately risk-matched to arecipient. Extended donor organs may have some of the following features: donor older than 55 years, mild left ventricularh ypertrophy,m ild coronary artery disease, hepatitis Bo rh epatitis Cp ositive donor,l eft ventriculardysfunction, small donor size, or high donor inotrope requirement. Because advanced donor age and prolonged ischemic time act synergistically to worsen post-transplant recipient survival,o rgans from older donors should not be allocated to ar ecipient if an ischemic time longer than 6hours is anticipated (10) . For donor hearts with CAD, somecen- ters have performed coronary artery bypass grafting at the timeoftransplantation and have reported good outcomes (11) . The outcomes for recipientsofhepatitis Cp ositive donor hearts have been poor overall. The majority of the recipientsw ill seroconvert and manydevelopactive hepatitis (12, 13) . Arecent study by Gasink et al. reports survival of 83% at 1year,53% at 5years, and 25% at 10 years for recipientsofhepatitis Cp ositive donor hearts (14) , whereas survival was 92% at 1year,77% at 5years, and 53% at 10 years for recipientso fh epatitis Cn egative donor hearts. The association between decreased survival and receipt of ahepatitis Cpositive donor heart was independent of recipient hepatitis Cstatus.
Donor and recipient matching arebased on weight (weight ratio of 0.8-1.2 is acceptable) and ABO compatibility.HLA matchingisnot acriteria for thoracic organ allocation. Once ad onor and recipient pair is identified, aprospectivespecific crossmatch between the donorand recipient is performedifthe PRA (panel reactive antibody) is >25%. Apositive crossmatch indicates the presence of anti-donor circulating antibodiesi nt he recipient which would likely lead to hyperacute rejection of the donor organ. In the event of ap ositive crossmatch, the donor organ cannot be accepted for that recipient.
Anew development in infant transplantation is the use of ABO-incompatible hearts. Infant transplantation is particularly limited by scarce availability of donor organs. In an attemptt ob roaden the donor pool, clinicians hypothesized that infants under 1y ear of age receiving ABO incompatibleh earts would not develop hyperacute rejection becausethey do not produce isohemagglutinins (anti-A or anti-B antibodies) nor is their complement system fully developed. In al andmark study,W est et al.d emonstrated the feasibility and long-term success of this strategy in 10 infants (15) .
TRENDS IN OPERATIVE TECHNIQUE
The original operative technique for orthotopic heart transplantationw as describedb yS humway and Lower in the 1960s (1). This simple and reproducible technique, often referred to as the "biatrial technique" or the "standardtechnique" made clinical heart transplantation possible. Following initiationofcardiopulmonary bypass, recipient cardiectomy is performed at the midatrial level, leaving bilateral atrial cuffs. The donor heart is then sewn in place with running biatrial, aortica nd pulmonary artery anastomoses. An early modification of thist echniquew as introduced by Barnardi n1 968 to address the high incidence of postoperative sinus node dysfunction (16) . In this variation, the incision in the donor heartright atrium is made from the opening of the IVC into the base of the right atrial appendage, rather than into the SVC, thereby avoiding the region of the sinoatrial node.
Disadvantages of the standardt echnique include sinus node dysfunction and distortion of atrioventricularg eometry,w hich can lead to atrial enlargement, dysynchronousatrial contraction, atrial thrombosis,and atrioventricular valvular insufficiency (17) . For these reasons, alternate moreanatomic methods of orthotopic transplantation have been developed. These include the "bicaval technique" (18, 19) and "total orthotopic heart transplantation technique" (20, 21) . In the bicaval technique, recipient cardiectomy is performed, leaving al eft atrial cufft hat spans the four pulmonary veins. Five anastomoses aret hen performed to bring together donor and recipient IVC, SVC, left atrium, aorta, and pulmonary artery.Disadvantages include risk of IVC or SVC stenosis or twisting and longer operative time than the standard technique. Modifications of the bicaval technique in which athin strip of right atrium is retained between the IVC and SVC to maintain their orientation have been described (22) . In the total orthotopic heart transplantation technique, the recipient left atrial cuffi sd ivided, leaving separate right and left pulmonary venous cuffs. Six anastomoses aret hen performed,b ringingt ogether donor and recipient IVC, SVC, right and left pulmonary vein cuffs, aorta, and pulmonary artery.Disadvantages includerisk of stenosis of the IVC, SVC, or pulmonary veins at the anastomotic level, and relative inaccessibility of the pulmonary venous anastomoses should bleeding occur.
In recent years, the bicaval technique has largely replaced the biatrial technique. In as urvey of 210 transplant centers,Aziz et al. found that 54% of centersu sed the bicaval technique most frequently, whereas 22% used the biatrial technique mostf requently and only 5% used the total orthotopic heart transplantation technique most frequently (23) . Reasons for converting to nonstandardt echniques included concern over tricuspid valve dysfunction, right ventricular performance, and arrhythmias or heart block. Av ariety of retrospective studiesh ave compared the end-points of atrioventricular valvular regurgitation, postoperative arrhythmias,a nd need for pacemakers in patients undergoing each of these operative techniques (24, 25, 26) . In these reports, the incidence of tricuspid valvular regurgitation is consistently less in the bicaval or total techniques when compared to the biatrial technique. Moreover,the incidence of atrial arrhythmias and the need for pacing also appears to be less.
Tricuspid regurgitation (TR) occurring post-transplantation may be caused by multiple factors. These include distorted atrioventricular geometry,allograft dysfunction from poor preservation or long ischemic time (results in RV dilation and secondary TR), pulmonary hypertension with secondary TR, and damage to the subvalvular apparatus or leaflets from endomyocardial biopsy.S everal reports of tricuspid annuloplasty (sutureo rr ing) at the timeo fo rthotopic heartt ransplantation have been published which demonstrate efficacy and feasibility of this technique (27, 28) . Jeevanandam et al. prospectively studied 60 patients, half of which received bicaval orthotopich eart transplants andt he other half received bicaval heart transplant plus tricuspid suture annuloplasty.At6y ears, 23% of the first group had severeT R, whereas none of the annuloplasty group had greater than mild TR (28) .
Heterotopic heart transplantation is rarely used in clinical practice. This technique was first performed in humans by Barnardin1974 with the transplanted heart functioning as ab iologic left ventricular assist device (29) .The transplanted heart can be positioned to functiona se ither left ventricular or biventricular support.F or biventricular support, the donor IVC and right pulmonary veins arel igated, followed by anastomosis of the donor and recipient left atria, SVC, aortae, and pulmonary arteries. The SVC and aortic anastomoses arep erformed end-to-side, and ashort vascular graft is used to connect the pulmonary arteries. This technique can be used in recipientsw ith significant pulmonary hypertension who would other wise be at risk for right ventricular failurefollowing orthotopicheart transplantation. It may also be used in cases of donor/recipient size mismatch (small donorh eart relative to recipient size, with donor/recipient weight ratio <75%). Outcomes following heterotopic heart transplantation areconsiderably worse than orthotopic heart transplantation.N ewcomb et al. reported a4 -year survival of 51% in 20 patients who underwent heterotopic heart transplantation at their institution, compared with 76% in their cohort of 111 orthotopicheart transplantation patients (30) .
CURRENT TRENDS IN IMMUNOSUPPRESSION
Until immunological tolerance becomes aclinical reality,immunosuppression is necessarytoprevent rejection posttransplantation.Early failures in thefield of clinical heart transplantation werei nl arge part due to inadequate immunosuppression strategies. The introduction of cyclosporine in the 1980s heralded the beginning of an ew era of clinical heart transplantation.P ostoperative immunosuppression consisted of cyclosporine, azathioprine, and corticosteroids. Cyclosporine, acalcineurin inhibitor,blocks the production of interleukin-2, preventingTcell activation and proliferation. Significant side effects include hypertension,hyperlipidemia, gingival hyperplasia, neurotoxicity,and renal toxicity.Azathioprine, an inhibitor of purine biosynthesis, prevents Tc ell clonal expansion; its major adverse effect is bone marrows uppression. Corticosteroidsi nhibit Tc ell activity through the blockade of cytokine production.
In the last 20 years, newer agents have been introduced into clinicalheart transplantation. In the 1990s, tacrolimus (a calcineurin inhibitor), and mycophenolate mofetil (an antimetabolite) werei ntroduced.
Comparison of cyclosporine and tacrolimus in clinical trials has shown similar survival and freedom of acute rejection (31, 32, 33) . Tacrolimus has as lightly different side effect profile than cyclosporine, with its major toxicities beingdiabetes mellitus (new or worsening of current state), hypertension, and renal dysfunction. In general, the choice between cyclosporine and tacrolimus is based on institutional preference and the individual patient response and side effect profile. Kobashigawa et al. compared the efficacy of the two antimetabolites, azathioprineand mycophenolate mofetil (MMF) in ar andomized controlled study of 650 heart transplant patients. They found that the rate of acute rejection was 11%l ess in the MMF group than the azathioprine group; moreover, mortality at 1year was less in the MMF group (6.2% versus 11.4%) (34) . Based on this and other retrospective outcomestudies, most centers haveshifted to the use of MMF rather than azathioprine in triple drug regimens.Inthe 2006 ISHLTreport, 76% of the most recent cohort of heart transplant patients wereo n MMF at 1-yearfollow-up, whereas only 8% wereon azathioprine (2).
In the 2000s, sirolimus and everolimus, proliferation signal inhibitors(block cell-cycle progression in response to IL-2) werei ntroduced. In ar andomized study of 92 patients, Keogh et al. found similar survival in patients treated with cyclosporine/sirolimus/steroids as those treated with cyclosporine/ azathioprine/steroids (35) . However,the incidence of acute rejection was lower in the sirolimus arm than the azathioprine arm (32% vs 56%) and the incidence of vasculopathy by intravascular ultrasound (IVUS) was less in the sirolimus arm. Eisen et al. compared the regimen of cyclosporine/everolimus/steroids to cyclosporine/azathioprine/steroids (36) . They also found al ower incidence of graft vasculopathy by IVUS technique (30-36% in the everolimus arms vs. 53% in the azathioprine arm). Unfortunately,wound complications have been higher in patients being treated with proliferation signal inhibitors, which limits their use, particularly early after transplantation.
Other interesting trends in immunosuppression include the development of steroid-free maintenance immunosuppression protocols (37, 38) . Reports of early steroid tapering have been published, and the overall trend is to taper offs teroids in the first 4-12 months after transplantation if possible. In the most recent ISHLTr eport, 77% of patients wereo np rednisone at 1y ear post-transplantation, whereas only 61% wereonprednisone at 5years post-transplantation (2).
Another adjunct to triple-drug regimens is antilymphocyte inductiont herapy.S everal agents,i ncluding ATG( antithymocyte globulin), OKT3, and the anti-IL-2 receptor antibodies (daclizumaba nd basiliximab) areused in clinical practice. These agents can be used to rapidly depleteTc ells (ATG and OKT3) or block theira ctivation (daclizumaba nd basiliximab). ISHLTd ata demonstrates that perioperative anti-lymphocyte antibody use increased from 41% in 1996, to 45% in 2000, and to 51% in 2004 (2). Induction therapy can also be used as ac omponent of sequential therapy in patientswith preoperative renal insufficiency (39) . In this strategy,p erioperative immunosuppression consists of an antimetabolite, steroids,a nd an anti-lymphocyte antibody preparation. Calcineurin inhibitors arenot introduced until 1-2 weeks postoperatively.
ACUTE REJECTION:TRENDS IN SURVEILLANCE AND TREATMENT STRATEGIES
The risk of acute rejection is highest during the first few months after transplantation and persists at a low constant level thereafter.M ost heart transplant patients will experience at least one episode of acute rejection,a nd therei sas mallm ortalityr isk associated with each of these episodes. Thereare no specificclinical signs for acute rejection, andpresentation mayrangefromthe asymptomatic patienttoone with complete hemodynamicc ollapse. Because of this, routine surveillance protocols using percutaneous transjugular endomyocardial biopsy have been adopted to provide early detection of subclinical acute rejection. The ISHLThas developed ahistologic grading scale for acutecellularand humoral rejection that helps guide the decision of when to initiate treatment for acute rejection (40) . Even so, biopsy-negative acute rejection occurs. This may reflect sampling error, or alternatively,b iopsy-negative acute rejection may be an antibody-mediated process that is poorly detected with conventional histologictechniques.
Endomyocardial biopsy is invasive,p otentially morbid, and costly.T herefore, newer strategies for rejection surveillance areb eing explored. These include genomic and proteonomic techniques to define the genetic/protein profile of acute rejection (41) . Noninvasive imaging techniques, including MRI, MR spectroscopy,and tissue Doppler imaging, may have ar ole in the early diagnosis of acute rejection. Intramyocardial electrograms have also been used successfully to monitor graft function, thought his requires implantation of apacemaker device at the time of transplantation (42) .
UNDERSTANDING CHRONIC REJECTION: CORONARYARTERYV ASCULOPATHY
Coronary artery vasculopathy (CAV) is aprogressive neointimal thickening that preferentially affects small and medium sized arteries of the allograft (43) . It can result in localizedischemia and ultimately,graft failure. It is aleading cause of late death after transplantation. CAVi st hought to be af orm of chronic rejection and risk factors include both alloantigen-dependent and alloantigen-independent factors, including number and severity of acute rejection episodes, HLA mismatching, ischemia-reperfusion injury,C MV infection, older donor or recipient age, hypertension, hyperlipidemia ,and donor or recipient male sex.
The ISHLTreports an incidence of CAVof7.9% at 1y ear,3 2.1% at 5y ears, and 44.3% at 8y ears posttransplantation (2). Treatment for CAVi sl imited; coronary artery bypass grafting is rarely possible because of the diffuse natureofthe disease. Percutaneous interventions, including angioplastya nd stenting, rarely have longterme fficacy. Ultimately,t he only treatment is retransplantation,but the outcomes for this areworse than primary transplantation, with 1-year survival of 56% and 5y ear survival of 38% (44) .
Because treatment for CAVislimited, the main focus is on prevention. Risk factor modification,including control of hyperlipidemia, hypertension, and hyperglycemia, may limit development of the disease. Episodes of acute rejection should be limited with appropriate surveillance and treatment and prophylaxis against CMV infection should be routine in atrisk patients. The proliferation signal inhibitors (sirolimus and everolimus) appear to limit the development of CAVand may see agrowing role in maintenance immunosuppression in the future.
CONCLUSIONS
With nearly four decades of experience with clinical heart transplantation,t his therapy continues to see new areas of growth and improvement. For select patients with end-stage heart disease,transplantation offers prolonged survival and improved quality of life. Widespread applicability of this therapy hasbeen limited by as mall donor pool, and futurea reas for growth will includet olerance induction as well as other non-transplant alternatives, including valvular repair and surgical ventricular restoration and the use of mechanical assist devices as destination therapy.
